Brief: Liquidia Says Files Litigation To Challenge Regulatory Exclusivity Blocking Access To Yutrepi Inhalation Powder For Patients Suffering With Pah And Ph-Ild
22/08/2024 12:30
Aug 22 (Reuters) - Liquidia Corp LQDA.O :
* LIQUIDIA FILES LITIGATION TO CHALLENGE REGULATORY
EXCLUSIVITY
BLOCKING ACCESS TO YUTREPIA™ (TREPROSTINIL) INHALATION POWDER
FOR PATIENTS SUFFERING WITH PAH AND PH-ILD
* LIQUIDIA - FINAL APPROVAL OF YUTREPIA (TREPROSTINIL)
INHALATION
POWDER IS CURRENTLY DELAYED UNTIL AFTER EXPIRATION OF
EXCLUSIVITY ON MAY 23, 2025
Source text for Eikon: ID:nGNX230FJv
Further company coverage: LQDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liquidia
See all newsUS STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing